Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Prosperity Financial Group Inc.

Prosperity Financial Group Inc. raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,137 shares of the medical equipment provider’s stock after purchasing an additional 464 shares during the quarter. Prosperity Financial Group Inc.’s holdings in Lantheus were worth $454,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC increased its position in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after purchasing an additional 100 shares during the last quarter. UMB Bank n.a. raised its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the period. GAMMA Investing LLC lifted its position in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division boosted its stake in Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after buying an additional 162 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 3.7 %

LNTH stock opened at $90.52 on Monday. The business has a 50 day moving average price of $103.13 and a 200 day moving average price of $96.93. The stock has a market cap of $6.29 billion, a price-to-earnings ratio of 15.06 and a beta of 0.51. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Analyst Ratings Changes

Several equities analysts have recently commented on LNTH shares. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. JMP Securities cut their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.